Background/aim Transient elastography is a relatively new, noninvasive method of measuring liver stiffness. This study aimed to evaluate the diagnostic accuracy of transient elastography and other noninvasive methods for the diagnosis of esophageal varices (EV) in patients with cirrhosis. Methods This cross-sectional study graded EV according to size in 145 consecutive patients with cirrhosis who underwent endoscopy, Fibroscan, and other noninvasive diagnostic methods. The accuracy of these diagnostic methods in diagnosing EV was evaluated on the basis of area under receiver operating characteristic (AUROC) curves.
Introduction
Variceal bleeding is a major complication of chronic liver disease and is associated with significant morbidity and mortality. A 15-year data set showed that ∼ 30-50% of cirrhotic patients died within 6 weeks of their first variceal bleed [1] . Among the survivors, 60% bled again and 30% died in the following year. Because of medical advances in the diagnosis and treatment of esophageal varices (EV), the rates of hospitalization, 6-week, and overall mortality because of variceal bleeding decreased to 14.2, 17.5, and 33.5%, respectively. The rebleeding rate also decreased to 29% [2] .
According to the American Association for the Study of Liver Diseases (AASLD) guidelines, all cirrhotic patients should undergo esophagogastroduodenoscopy (simply referred to as endoscopy) to examine varices upon diagnosis to identify those patients at high risk and to provide continuous screening throughout the course of the disease [3] . Recent guidelines of the American Society for Gastrointestinal Endoscopy recommend the same [4] . Esophagogastroduodenoscopy is the gold standard for the detection and staging of EV; however, it has limitations [5] . Endoscopy is an invasive technique, and some patients may be reluctant to agree to this procedure, especially for screening purposes [6] . Furthermore, the increasing cost of repeated endoscopy will lead to a significant financial burden [7] .
Several noninvasive modalities have been suggested to replace endoscopic screening for the detection of varices. These methods include two-dimensional ultrasound [8] , video capsule endoscopy [9] , computed tomography [10] , and noninvasive blood tests to detect significant fibrosis, such as tests for the aspartate transaminase (AST)-to-platelet ratio index (APRI), fibrosis-4, Forns Index, and Lok Score [11] , platelet count/spleen diameter ratio, and esophageal varices risk score [12] .
One of the noninvasive modalities used is transient elastography (Fibroscan) , which measures the stiffness (or elasticity) of the hepatic parenchyma using both ultrasound (5 MHz) and low-frequency (50 Hz) elastic waves. Fibroscan has been shown in many studies to be a reliable and useful tool for the assessment of liver fibrosis [13] . Because the development of portal hypertension is secondary to liver fibrosis in most cases, studies have found a correlation between liver stiffness and portal hypertension, as assessed on the basis of the hepatic venous pressure gradient [2, [14] [15] [16] . Thus, Fibroscan has been suggested to be a noninvasive tool for screening and diagnosing EV.
Data on the accuracy of Fibroscan in predicting the presence of EV are limited, and the results are inconsistent. The limitations of these studies are as follows: retrospective nature, small patient numbers, and inclusion of patients with differing cirrhosis-related etiologies. Sporea et al. [17] suggested that Fibroscan scores differ depending on the etiology of the underlying liver cirrhosis and that different cutoff values should be considered accordingly. A recently published study from Egypt evaluated the ability of Fibroscan to predict the presence and grade of EV in 32 patients with hepatitis C virus (HCV)-related cirrhosis. This study showed that Fibroscan values were significantly higher in the presence of EV than in their absence; using a cutoff value of 29.7 kPa, the sensitivity and specificity obtained were 95 and 67%, respectively [18] . However, it was not found to be a reliable tool for detecting EV in a recently published study from France [19] . Hence, this study aimed to measure the diagnostic accuracy of Fibroscan for EV in patients with cirrhosis of various etiologies and to correlate the results obtained with various hematological investigations that are routinely performed in these patients.
Methods

Study design, setting, and study population
This cross-sectional study was carried out from January 2010 to January 2013 in a tertiary care center in Saudi Arabia. A total of 145 patients with cirrhosis were recruited consecutively from the outpatient clinic. The diagnosis of cirrhosis was made on the basis of liver biopsy or the presence of at least two of the following: (a) platelet count less than 90 000/l, (b) radiological (ultrasonography or computed tomography) evidence of cirrhosis, and (c) at least two signs of liver dysfunction, including albumin level less than 30 g/l, international normalized ratio (INR) of 1.5 or more, and bilirubin level more than 35 μmol/l. Patients younger than the age of 18 years, patients who were unable to provide informed consent, patients with noncirrhotic chronic liver disease, patients with acute liver failure, patients whose transaminase levels were more than three times the normal upper limit, and patients for whom Fibroscan examination could not be performed were excluded.
Data collection
All patients were subjected to a full assessment of clinical history, examination, laboratory tests (including a complete blood count), and evaluations of the coagulation profile, liver function tests, HCV antibody, hepatitis B virus markers, autoimmune serology, and abdominal ultrasonography. All patients underwent transient elastography (Fibroscan; EchoSens, Paris, France). A success rate of more than 60% was considered reliable in 10 validated measurements with an interquartile range less than 30% of the median [20] . The Fibroscan was performed by a single certified, trained investigator.
Endoscopy performance and grading of EV Upper gastrointestinal endoscopy was performed by experienced endoscopists who were unaware of the Fibroscan result. EV were classified as described by Beppu et al. [21] as follows: grade I, EVs are small and straight; grade II, varices are tortuous and occupy less than onethird of the esophageal lumen; and grade III, varices are large and occupy more than one-third of the esophageal lumen. We divided our patients into three groups: group 1, no varices; group 2, grade I (small) varices; and group 3, grades II and III (large) varices.
Ethical considerations
The protocol used was approved by the local Institutional Review Board and conformed to the ethical guidelines of the Declaration of Helsinki. Written informed consent was obtained from each patient before each procedure.
Statistical analysis
Data were analyzed utilizing SPSS, version 17.0 (SPSS Inc., Chicago, Illinois, USA). All results are presented either as the mean SD or as the frequency (%), as appropriate. Group differences were analyzed using an analysis of variance and Student's t-test to analyze differences between patients in group 1 versus groups 2 and 3 and between patients in groups 1 and 2 versus group 3. χ 2 -tests were used to measure the differences between categorical variables.
Pearson correlations (r) were computed to measure the association of Fibroscan readings with the results of hematological tests, such as platelet and white cell counts; hemoglobin, INR, albumin, bilirubin, alanine transaminase (ALT), AST and alkaline phosphatase levels; and APRI and ALT-to-AST ratio. Correlation coefficients (γ) were computed to measure the association of Fibroscan fibrosis staging and EV grades by endoscopy. P-values less than 0.05 were considered significant.
The diagnostic accuracies of Fibroscan for predicting the presence of EV (groups 2 and 3) compared with no varices (group 1); the presence of large varices (group 3) compared with small and no varices (groups 1 and 2); and various grades of varices compared with no varices were measured using receiver operating characteristic (ROC) curve analysis. ROC curve analyses were also carried out for noninvasive serum markers to compare patients with no varices with patients with varices and for diagnosing the presence of EV (groups 2 and 3) versus the presence of large varices (group 3). Areas under ROC (AUROC) of greater than 0.9 indicate high accuracy, values of 0.7 to 0.9 indicate moderate accuracy, and values of 0.5 to 0.7 indicate low accuracy for the test [22] . Cutoff values were determined, and the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated for these cutoff values.
Results
Twenty-two patients were excluded because of failure to perform liver elastography because of ascites or obesity. A total of 123 patients were included in the final analysis. The patients' mean age was 58. 8 Patients in groups 2 and 3 were significantly older and had lower platelet counts, lower albumin levels, higher INR, higher APRI, and lower ALT-to-AST ratio than patients in group 1 ( Table 1 ). The platelet count was significantly lower in patients in group 3 than in patients in groups 1 and 2 ( Table 2 ).
The mean Fibroscan success rate was 83.9% (mean interquartile range 3.3). Fibroscan interpretation of the stage of fibrosis showed a strong positive correlation with varices grade according to endoscopy in patients with nonviral-related cirrhosis (γ = 0.747, P < 0.001) and in those with a viral etiology (γ = 1, P < 0.01). Fibroscan showed a significant negative correlation with platelet count, albumin level, and ALT-to-AST ratio but also showed a significant positive correlation with alkaline phosphatase, AST, and APRI (Table 3 ).
In non-viral-related cirrhosis, APRI, INR, and Fibroscan presented low accuracy for the diagnosis of patients with EV compared with those without varices (AUROC values of 0.68, 0.67, and 0.66, respectively). Platelet count, albumin, and ALT-to-AST ratio presented AUROCs less than 0.5 and thus showed poor accuracy for the diagnosis of EV. For the diagnosis of EV in patients with a viral etiology, Fibroscan showed better accuracy (AUROC = 0.704); similarly, APRI and INR were similar in accuracy to Fibroscan (APRI, AUROC = 0.703; INR, AUROC = 0.69). The ROC curves for diagnosing EV in patients with and without viral-related cirrhosis are shown in Figs 1 and 2 .
The optimal cutoff value for use in Fibroscan measurements for the detection of EV in non-viral-related cirrhosis was found to be 16.9 kPa. At this cutoff value, Fibroscan showed a sensitivity of 83.8%, a specificity of 36.7%, a PPV of 66.7%, an NPV of 60.0%, and a diagnostic accuracy of 65%. The optimal cutoff value for use in Fibroscan measurements for the diagnosis of EV in patients with viral-related cirrhosis was 19.9 kPa. At this cutoff value, Fibroscan showed a sensitivity of 83.4%, a specificity of 50.0%, a PPV of 71.4%, an NPV of 66.7%, and a diagnostic accuracy of 70.0%.
Fibroscan showed low accuracy for the diagnosis of large varices in patients with non-viral-related cirrhosis (AUROC = 0.57) and in patients with viral-related cirrhosis (AUROC = 0.56). APRI, INR, platelet count, albumin, and ALT-to-AST ratio showed AUROCs of less than 0.6, indicating poor accuracy in the diagnosis of large varices. Compared with its accuracy in predicting no varices, Fibroscan was found to be moderately accurate for diagnosing grade I varices in non-viral-cirrhotic patients (AUROC = 0.703) and was better at diagnosing varices in patients with viral-related cirrhosis (AUROC = 0.766). However, Fibroscan was found to be less accurate for the diagnosis of grade II and grade III varices in patients with non-viral-related cirrhosis (AUROCs of 0.616 and 0.652, respectively) and in those with a viral etiology (AUROCs of 0.613 and 0.685, respectively).
Discussion
The results of this study suggest that endoscopy should remain the main method for EV screening, although Fibroscan can be considered a reasonable alternative. The results also show that Fibroscan showed a greater accuracy (although modestly so) for diagnosing EV in patients with liver cirrhosis with a viral etiology than in liver cirrhosis caused by other etiologies. Data on the accuracy of Fibroscan in predicting the presence of EV are limited, and the results are inconsistent. The limitations of these studies are as follows: retrospective nature, small patient numbers, and inclusion of patients with different cirrhosis-related etiologies. A recently published study suggested that Fibroscan scores differ depending on the etiology of the underlying liver cirrhosis and that different cutoff values should be considered accordingly [17] . The accuracy of Fibroscan in patients with cirrhosis with a viral etiology obtained here is consistent with that obtained by Saad and colleagues, who evaluated the ability of Fibroscan to predict the presence and grade of EV in 32 patients with HCV-related cirrhosis. In that study, patients were classified into three groups according to the presence and size of EV. The authors showed that Fibroscan values were significantly higher in the presence of EV than in their absence; using a cutoff value of 29.7 kPa, the sensitivity and specificity obtained were 95 and 67%, respectively. The authors also showed that patients with larger varices presented significantly higher Fibroscan values. The sensitivity and specificity obtained using a cutoff value of 38.2 kPa were 100 and 77%, respectively. The data suggest that the noninvasive Fibroscan can predict the presence and size of EV with high sensitivity [18] . In our study, the HCV patients in group 1 had a mean liver stiffness of 24.2 kPa compared with 36.8 kPa for those in groups 2 and 3 (P = 0.004); although significant, these values are lower than those reported by Saad and colleagues. This discrepancy might be because of the smaller sample size (n =32) in the latter study. However, in our study, the accuracy of predicting the presence of EV was modest in patients with non-viral-related cirrhosis. Similar findings were reported by Stefanescu and colleagues, who evaluated 231 consecutive cirrhotic patients with various underlying liver diseases. For liver stiffness of greater than 30.8 kPa, the PPV was 47.3%, NPV was 81%, and diagnostic accuracy was 68.32%. The authors also suggested that combining transient elastography with other noninvasive diagnostic methods would result in a successful algorithm for predicting large varices [11] . Vizzutti et al. correlated well with EV grade. AUROC values for liver stiffness measurement were 0.84 in the presence of varices and 0.83 in the presence of varices of at least grade 2. The authors also showed that liver stiffness measurement values of less than 19 kPa were highly predictive of the absence of large EV; however, no such correlation was established in our study [24] . Therefore, our data suggest that endoscopy should remain the main method for EV screening, although Fibroscan can be used if endoscopy cannot be performed for any reason; for example, if endoscopy is not available, not feasible, associated with a high risk, or refused by the patient; in addition, Fibroscan can be used for follow-up screening/monitoring. In recent years, multiple noninvasive serum markers have been introduced to assess fibrosis with promising results. More recently, these markers have been used to predict the presence of EV, with variable results. In the current study, the diagnostic accuracies of APRI and INR were found to be modest and close to that of Fibroscan for EV in patients with non-viral-related cirrhosis, with AUROC values of 0.68, 0.67, and 0.66, respectively. APRI alone provided similar accuracy to Fibroscan in patients with viral-related cirrhosis (AUROCs of 0.703 and 0.704, respectively). The performance of APRI in predicting the presence of EV differed among several studies and was suboptimal (AUROCs of between 0.54 and 0.71). In the current study, APRI and INR were also less accurate in detecting large varices in patients with non-viral-related cirrhosis (AUROCs of 0.62 and 0.542, respectively) and in patients with a viral etiology (AUROCs of 0.61 and 0.539, respectively). The platelet count, albumin, and ALT-to-AST ratio showed AUROCs of less than 0.5, indicating poor accuracy in the diagnosis of large varices. In a large multicenter European study that investigated the diagnostic accuracy of a series of simple and clinically available serum markers, APRI performed poorly (AUC 0.63). However, the authors suggested that combining various noninvasive diagnostic methods might result in an improved diagnostic accuracy, achieving an NPV of greater than 90% to exclude clinically relevant EV [11, 25] .
Our study is one of the first to report on the use of Fibroscan for predicting EV in the Middle East. Unlike the regions in which most other studies have been carried out, most Middle East countries have a predominantly genotype 4 hepatitis C burden [26] and a predominantly genotype D hepatitis B infection [27] , and have a relatively higher prevalence of schistosomiases, obesity, and diabetes. These differences might explain the variations in the results reported by various groups [28] . These results pave the way for future, larger prospective studies.
